BACKGROUND: Prostate cancer is the second leading cause of cancer death in men, and early detection is essential to reduce mortality and increase survival. delta-Catenin is a unique beta-catenin superfamily protein primarily expressed in the brain but is upregulated in human prostatic adenocarcinomas. Despite its close correlation with the disease, it is unclear whether delta-catenin presents the potential in prostate cancer screening because it is an intracellular protein. In this study, we investigated the hypothesis of delta-catenin accumulation in the urine of prostate cancer patients and its potential pathways of excretion into extracellular milieu. METHODS: Prostate cancer cell cultures, human tissue biopsies, and voided urines were characterized to determine extracellular delta-catenin accumulation and co-isolation with exosomes/prostasomes. RESULTS: We identified delta-catenin in culture media and in the stroma of human prostate cancer tissues. In PC-3 cells in culture, delta-catenin was partially co-localized and co-isolated with raft-associated membrane protein caveolin-1 and glycosylphosphatidylinositol-anchored protein CD59, suggesting its potential excretion into extracellular milieu through exosome/prostasome associated pathways. Interference with endocytic pathway using wortmannin did not block prostasome excretion, but delta-catenin overexpression promoted the extracellular accumulation of caveolin-1. delta-Catenin, caveolin-1, and CD59 were all detected in cell-free human voided urine prostasomes. delta-Catenin immunoreactivity was significantly increased in the urine of prostate cancer patients (P < 0.0005). CONCLUSIONS: This study demonstrated, for the first time, the extracellular accumulation of delta-catenin in urine supporting its potential utility for non-invasive prostate cancer detection. 2008 Wiley-Liss, Inc.
BACKGROUND:Prostate cancer is the second leading cause of cancer death in men, and early detection is essential to reduce mortality and increase survival. delta-Catenin is a unique beta-catenin superfamily protein primarily expressed in the brain but is upregulated in humanprostatic adenocarcinomas. Despite its close correlation with the disease, it is unclear whether delta-catenin presents the potential in prostate cancer screening because it is an intracellular protein. In this study, we investigated the hypothesis of delta-catenin accumulation in the urine of prostate cancerpatients and its potential pathways of excretion into extracellular milieu. METHODS:Prostate cancer cell cultures, human tissue biopsies, and voided urines were characterized to determine extracellular delta-catenin accumulation and co-isolation with exosomes/prostasomes. RESULTS: We identified delta-catenin in culture media and in the stroma of human prostate cancer tissues. In PC-3 cells in culture, delta-catenin was partially co-localized and co-isolated with raft-associated membrane protein caveolin-1 and glycosylphosphatidylinositol-anchored protein CD59, suggesting its potential excretion into extracellular milieu through exosome/prostasome associated pathways. Interference with endocytic pathway using wortmannin did not block prostasome excretion, but delta-catenin overexpression promoted the extracellular accumulation of caveolin-1. delta-Catenin, caveolin-1, and CD59 were all detected in cell-free human voided urine prostasomes. delta-Catenin immunoreactivity was significantly increased in the urine of prostate cancerpatients (P < 0.0005). CONCLUSIONS: This study demonstrated, for the first time, the extracellular accumulation of delta-catenin in urine supporting its potential utility for non-invasive prostate cancer detection. 2008 Wiley-Liss, Inc.
Authors: S A Tahir; G Yang; S Ebara; T L Timme; T Satoh; L Li; A Goltsov; M Ittmann; J D Morrisett; T C Thompson Journal: Cancer Res Date: 2001-05-15 Impact factor: 12.701
Authors: Kwonseop Kim; Anna Sirota; Yan-hua Chen Yh; Shiloh B Jones; Ronald Dudek; George W Lanford; Chittam Thakore; Qun Lu Journal: Exp Cell Res Date: 2002-05-01 Impact factor: 3.905
Authors: Salahaldin A Tahir; Chengzhen Ren; Terry L Timme; Yehoshua Gdor; Ron Hoogeveen; Joel D Morrisett; Anna Frolov; Gustavo Ayala; Thomas M Wheeler; Timothy C Thompson Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: Michelle Jane Burger; Michelle Anne Tebay; Patricia Anne Keith; Hema Mali Samaratunga; Judith Clements; Martin Francis Lavin; Robert Alexander Gardiner Journal: Int J Cancer Date: 2002-07-10 Impact factor: 7.396
Authors: Dongmin Gu; Nam Ky Tonthat; Moonsup Lee; Hong Ji; Krishna P Bhat; Faith Hollingsworth; Kenneth D Aldape; Maria A Schumacher; Thomas P Zwaka; Pierre D McCrea Journal: J Biol Chem Date: 2011-05-11 Impact factor: 5.157
Authors: Alba Simats; Laura Ramiro; Teresa García-Berrocoso; Ferran Briansó; Ricardo Gonzalo; Luna Martín; Anna Sabé; Natalia Gill; Anna Penalba; Nuria Colomé; Alex Sánchez; Francesc Canals; Alejandro Bustamante; Anna Rosell; Joan Montaner Journal: Mol Cell Proteomics Date: 2020-08-31 Impact factor: 5.911